Post-mortem examination of high mortality in patients with heart failure and atrial fibrillation
- PMID: 36195871
- PMCID: PMC9533594
- DOI: 10.1186/s12916-022-02533-8
Post-mortem examination of high mortality in patients with heart failure and atrial fibrillation
Abstract
Background: The prevalence of combined heart failure (HF) and atrial fibrillation (AF) is rising, and these patients suffer from high rates of mortality. This study aims to provide robust data on factors associated with death, uniquely supported by post-mortem examination.
Methods: A retrospective cohort study of hospitalized adults with a clinical diagnosis of HF and AF at a tertiary centre in Romania between 2014 and 2017. A standardized post-mortem examination was performed where death occurred within 24 h of admission, when the cause of death was not clear or by physician request. National records were used to collect mortality data, subsequently categorized and analysed as HF-related death, vascular death and non-cardiovascular death using Cox proportional hazards regression.
Results: A total of 1009 consecutive patients with a mean age of 73 ± 11 years, 47% women, NYHA class 3.0 ± 0.9, left ventricular ejection fraction (LVEF) 40.1 ± 11.0% and 100% anticoagulated were followed up for 1.5 ± 0.9 years. A total of 291 (29%) died, with post-mortems performed on 186 (64%). Baseline factors associated with mortality were dependent on the cause of death. HF-related death in 136 (47%) was associated with higher NYHA class (hazard ratio [HR] 2.45 per one class increase, 95% CI 1.73-3.46; p < 0.001) and lower LVEF (0.95 per 1% increase, 0.93-0.97; p < 0.001). Vascular death occurred in 75 (26%) and was associated with hypertension (HR 2.83, 1.36-5.90; p = 0.005) and higher LVEF (1.08 per 1% increase, 1.05-1.11; p < 0.001). Non-cardiovascular death in 80 (28%) was associated with clinical obesity (HR 2.20, 1.21-4.00; p = 0.010) and higher LVEF (1.10 per 1% increase, 1.06-1.13; p < 0.001). Across all causes, there was no relationship between mortality and AF type (p = 0.77), HF type (p = 0.85) or LVEF (p = 0.58).
Conclusions: Supported by post-mortem data, the cause of death in HF and AF patients is heterogeneous, and the relationships with typical markers of mortality are critically dependent on the mode of death. The poor prognosis in this group demands further attention to improve management beyond anticoagulation.
Keywords: Atrial fibrillation; Autopsy; Heart failure; Mortality; Post-mortem.
© 2022. The Author(s).
Conflict of interest statement
All authors have completed the ICMJE uniform disclosure form and declare the following: Otilia Tica received salary funding from the EU/EEPIA Innovative Medicines Initiative (BigData@Heart 116074) and Amomed Pharma, awarded to Professor Kotecha. Professor Kotecha reports grants from the National Institute for Health Research (NIHR CDF-2015–08-074 RATE-AF; NIHR HTA-130280 DaRe2THINK), the British Heart Foundation (PG/17/55/33087 and AA/18/2/34218), EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074), the European Society of Cardiology supported by educational grants from Boehringer Ingelheim/BMS-Pfizer Alliance/Bayer/Daiichi Sankyo/Boston Scientific, the NIHR/University of Oxford Biomedical Research Centre and British Heart Foundation/University of Birmingham Accelerator Award (STEEER-AF NCT04396418) and Amomed Pharma and IRCCS San Raffaele/Menarini (Beta-blockers in Heart Failure Collaborative Group NCT0083244), in addition to personal fees from Bayer (Advisory Board), AtriCure (Speaker fees), Amomed (Advisory Board), Protherics Medicines Development (Advisory Board) and Myokardia (Advisory Board). Dr. Ovidiu Tica, Dr. deBono, Professor Popescu and Professor Gkoutos declare that they have no competing interests. Dr. Bunting was the research fellow for the RATE-AF trial funded by the NIHR (NIHR CDF-2015–08-074) and has been awarded a grant from the University of Birmingham’s British Heart Foundation Accelerator Award (BHF AA/18/2/34218) and the British Heart Foundation Fellowship scheme (FS/CDRF/21/21032).
Figures



Similar articles
-
Effect of Atrial Fibrillation on Mortality, Stroke Risk, and Quality-of-Life Scores in Patients With Heart Failure (from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF]).Am J Cardiol. 2017 Jun 1;119(11):1763-1769. doi: 10.1016/j.amjcard.2017.02.050. Epub 2017 Mar 16. Am J Cardiol. 2017. PMID: 28416199 Clinical Trial.
-
Prognoses and risk stratification of thrombus-associated events in heart failure patients without atrial fibrillation.ESC Heart Fail. 2024 Dec;11(6):3687-3701. doi: 10.1002/ehf2.14952. Epub 2024 Jul 9. ESC Heart Fail. 2024. PMID: 38979876 Free PMC article.
-
Prognosis and treatment strategies for atrial fibrillation in heart failure with mildly reduced ejection fraction.Eur J Prev Cardiol. 2024 Aug 22;31(11):1372-1384. doi: 10.1093/eurjpc/zwae185. Eur J Prev Cardiol. 2024. PMID: 38825871
-
Atrial fibrillation and risk of adverse outcomes in heart failure with reduced, mildly reduced, and preserved ejection fraction: A systematic review and meta-analysis.J Cardiovasc Electrophysiol. 2024 Apr;35(4):715-726. doi: 10.1111/jce.16209. Epub 2024 Feb 13. J Cardiovasc Electrophysiol. 2024. PMID: 38348517
-
Clinical outcomes of patients with heart failure and atrial fibrillation: Experience from an outpatient heart failure clinic in Colombia.Curr Probl Cardiol. 2024 Dec;49(12):102841. doi: 10.1016/j.cpcardiol.2024.102841. Epub 2024 Sep 4. Curr Probl Cardiol. 2024. PMID: 39242064 Review.
Cited by
-
Are the Four Pillars the Ideal Treatment for the Elderly?Cardiology. 2023;148(4):296-299. doi: 10.1159/000531467. Epub 2023 Jun 8. Cardiology. 2023. PMID: 37290402 Free PMC article. No abstract available.
-
A review of the impact, pathophysiology, and management of atrial fibrillation in patients with heart failure with preserved ejection fraction.Am Heart J Plus. 2023 Jul 18;33:100309. doi: 10.1016/j.ahjo.2023.100309. eCollection 2023 Sep. Am Heart J Plus. 2023. PMID: 38510554 Free PMC article. Review.
-
Breaking the Cycle of Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation.Card Fail Rev. 2022 Nov 18;8:e32. doi: 10.15420/cfr.2022.03. eCollection 2022 Jan. Card Fail Rev. 2022. PMID: 36644646 Free PMC article. Review.
-
Efficacy and safety of intravenous beta-blockers in acute atrial fibrillation and flutter is dependent on beta-1 selectivity: a systematic review and meta-analysis of randomised trials.Clin Res Cardiol. 2024 Jun;113(6):831-841. doi: 10.1007/s00392-023-02295-0. Epub 2023 Sep 1. Clin Res Cardiol. 2024. PMID: 37658166 Free PMC article.
References
-
- Li X, Tse VC, Au-Doung LW, Wong ICK, Chan EW. The impact of ischaemic stroke on atrial fibrillation-related healthcare cost: a systematic review. Europace. 2017;19(6):937–947. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous